Diagnosis of Eosinophilic Esophagitis – Evidence‑Based Guideline Summary

1. Core Diagnostic Criteria

Endoscopic examination with esophageal biopsies demonstrating ≥15 eosinophils per 0.3 mm² (high‑power field), in a patient with symptoms of esophageal dysfunction (e.g., dysphagia, food impaction, chest pain, heartburn), after excluding alternative causes of esophageal eosinophilia, is the most accurate method to diagnose EoE. 1
The diagnosis is clinicopathological, requiring integration of three elements:

Sampling strategy: Obtain at least 6 biopsies from a minimum of two distinct esophageal locations (proximal + distal or distal + mid) to achieve the highest diagnostic yield. 1
Diagnostic accuracy with six biopsies: Sensitivity reaches 97–100 %, confirming that this sampling density reliably captures the patchy eosinophilic infiltrate characteristic of EoE. 1

Aspect	Recommendation
Targeted biopsies	Sample visible mucosal abnormalities (white spots, furrows, rings).
Non‑targeted biopsies	Sample normal‑appearing mucosa to detect disease in endoscopically silent areas.
Sites	Include both distal and middle esophagus as standard.

*Both targeted and non‑targeted biopsies should be combined to maximize detection. 3

PPI trial is not mandatory for establishing the diagnosis of EoE according to current consensus. 2
When feasible, withdrawing PPIs for ≥3 weeks before endoscopy improves diagnostic accuracy by eliminating drug‑induced histologic suppression. 4
PPI‑responsive EoE is classified as the same disease entity as PPI‑refractory EoE; both fall under the umbrella of eosinophilic esophagitis. 4
Co‑existence of gastro‑esophageal reflux disease (GERD) and EoE is recognized; clinicians should remain vigilant for overlapping pathology. 4

Pathology reports must include the peak eosinophil count per 0.3 mm² (standardized high‑power field). 1
Additional microscopic features that support the diagnosis should be documented:
4

Gastric and duodenal biopsies are recommended:
Repeat endoscopy should be considered if the initial biopsy is non‑diagnostic but clinical suspicion remains high (e.g., persistent typical symptoms or suggestive endoscopic signs). 4

The American Academy of Allergy, Asthma, and Immunology and the American Gastroenterological Association recommend that EGD may reveal characteristic endoscopic features of EoE, including esophageal rings, longitudinal furrows, whitish exudates, edema, diffuse esophageal narrowing, narrow-caliber esophagus, and esophageal lacerations, but these features are not pathognomonic for EoE 5, 6
Endoscopic findings alone have limited diagnostic utility, with only 38% of patients with endoscopic features suggestive of EoE confirmed to have the condition on biopsy, and 9.8% of patients with normal-appearing esophagus on endoscopy having histologic evidence of EoE 7, 8

The American Gastroenterological Association recommends that endoscopy with esophageal biopsy remains the only reliable diagnostic test for EoE, with multiple biopsies from at least two esophageal levels (proximal and distal) recommended to increase diagnostic yield 5, 7, 9
Targeting areas with visible inflammation when present increases diagnostic yield, and the optimal number of biopsies is 2-6 specimens, with 2 biopsies having 84% sensitivity, 3 biopsies having 97% sensitivity, and 6 biopsies having 100% sensitivity 5, 6, 9

Diagnosis requires symptoms of esophageal dysfunction, ≥15 eosinophils per high-power field on esophageal biopsy, and exclusion of other causes of esophageal eosinophilia, with isolated esophageal eosinophilia without corroborating symptoms and exclusion of other causes being insufficient for diagnosis 5, 6, 10, 11

The American Gastroenterological Association notes that proton pump inhibitor therapy may affect biopsy results, and patients on PPI therapy who have normal biopsies cannot be definitively ruled out for EoE, and gastric and duodenal biopsies should also be obtained in children and when clinically indicated in adults to exclude other causes of esophageal eosinophilia 5, 6, 11